Oak Associates’s Gyre Therapeutics GYRE Stock Holding History

Oak Associates’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-49	Closed	-$107K	–	161
2015 Q2	$107K	Hold	49	–	–	0.01%	172
2015 Q1	$114K	Hold	49	–	–	0.01%	176
2014 Q4	$101K	Hold	49	–	–	0.01%	184
2014 Q3	$97K	Hold	49	–	–	0.01%	181
2014 Q2	$173K	Hold	49	–	–	0.02%	174
2014 Q1	$183K	Hold	49	–	–	0.02%	177
2013 Q4	$160K	Buy	+49	New	+$193K	0.02%	177
2013 Q2	$164K	Buy	+49	New	+$186K	0.02%	162

Other funds holding GYRE

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Oak Associates's GYRE Position: Q3 2015 in Review

Oak Associates sold out of Gyre Therapeutics (GYRE) in Q3 2015, closing a stake of 49 shares — an estimated $107K sold.

Oak Associates first reported a position in GYRE in Q2 2013 and held it in 8 quarters. The position peaked at $183K in Q1 2014. 39 funds tracked by Wall St. Rank hold GYRE as of Q3 2015.

Oak Associates reported no remaining Gyre Therapeutics position as of Q3 2015 after selling out during the quarter.
Oak Associates sold 49 Gyre Therapeutics shares in Q3 2015, an estimated $107K.
Oak Associates first reported a position in Gyre Therapeutics in Q2 2013 and held it in 8 quarters.
Oak Associates's Gyre Therapeutics position peaked at $183K in Q1 2014.
39 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q3 2015.

Based on Oak Associates's 13F filing for Q3 2015, filed 16 Nov 2015.